Currently, Real World Evidence (RWE) refers to studies utilizing data obtained from “real world settings;” thus, it resides outside the tight controls of a clinical trial design. The concept of RWE is not new, but the buzz surrounding RWE and the emphasis for providing such data is, and demand continues to grow. What this means is that the field is constantly evolving, as are the ways to utilize such data to draw the best insight and value story of products. The opportunities in this area are vast, but RWE is not without challenges. There is still no standard process, it is difficult to access and identify the appropriate data sources and evaluating products in clinical practice is complex and time-consuming. The most successful outcomes will result from leveraging external partnerships to navigate a difficult market as well as the best data approach. Find out how some of the world’s largest pharmaceutical companies and most innovative biotechs are streamlining the way they identify, qualify and engage with CROs to ensure speed and proper data insight.